Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Baxter missed earnings and sales forecasts, posted a larger loss, and cut 2026 outlook, spurring a 14.6% stock drop.
Baxter International reported fourth-quarter 2025 sales of $2.97 billion, up 8% year-over-year but only 3% on an operational basis, missing analyst expectations.
Adjusted earnings per share were $0.44, below the $0.54 forecast, due to margin pressure, higher taxes, and a 900-basis-point drop in gross margin.
The company posted a net loss of $1.12 billion, worsening from last year’s $512 million loss, with the Kidney Care segment now classified as discontinued.
Despite growth in Advanced Surgery and Healthcare Systems, Pharmaceuticals and Injectables declined.
Baxter issued weak 2026 guidance, projecting flat to 1% sales growth and adjusted EPS of $1.85–$2.05, below the market’s $2.25 estimate, causing its stock to fall 14.6% in pre-market trading.
Baxter no cumplió con las previsiones de ganancias y ventas, registró una mayor pérdida y recortó las perspectivas para 2026, lo que provocó una caída de las acciones del 14,6%.